The stock of Abbvie Inc (NYSE:ABBV) last traded at $159.61, down -2.04% from the previous session.
ABBV stock price is now -5.67% away from the 50-day moving average and 0.73% away from the 200-day moving average. The market capitalization of the company currently stands at $281.85B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $200, Cantor Fitzgerald recently initiated with Overweight rating for Abbvie Inc (NYSE: ABBV). , while ‘HSBC Securities’ rates the stock as ‘Hold’
In other news, Donoghoe Nicholas, EVP, CHIEF BUS/STRAT OFFICER sold 21,082 shares of the company’s stock on Mar 20 ’24. The stock was sold for $3,716,757 at an average price of $176.30. Upon completion of the transaction, the EVP, CHIEF BUS/STRAT OFFICER now directly owns 55,903 shares in the company, valued at $8.92 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 18 ’24, EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan sold 58,949 shares of the business’s stock. A total of $10,539,508 was realized by selling the stock at an average price of $178.79. This leaves the insider owning 60,941 shares of the company worth $9.73 million. A total of 0.11% of the company’s stock is owned by insiders.
During the past 12 months, Abbvie Inc has had a low of $130.96 and a high of $182.89. As of last week, the company has a debt-to-equity ratio of 9.24, a current ratio of 0.94, and a quick ratio of 0.83. According to the stock market information, the enterprise value for the company is $338180145152, which is based on a 47.52 price-to-earnings ratio, a 7.57 price-to-earnings-growth ratio, and a beta of 0.58. The fifty day moving average price for ABBV is $168.7698 and a two-hundred day moving average price translates $158.4961 for the stock.
The latest earnings results from Abbvie Inc (NYSE: ABBV) was released for 2024-03-31. According to the Drug Manufacturers – General Company, earnings per share came in at 2.91, beating analysts’ expectations of 2.81 by 0.1. This compares to $0.14 EPS in the same period last year. The net profit margin was 10.94% and return on equity was 55.92% for ABBV. The company reported revenue of $12.31 billion for the quarter, compared to $12.22 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.7 percent. For the current quarter, analysts expect ABBV to generate $14B in revenue.
